Marta Olah

The paper uses CRISPR mapping to identify pharmacological targets for modulating microglial migration linked to Alzheimer's disease.

This study identifies cGAS as a key mediator of TDP-43 pathology in ALS and shows that its inhibition reduces RNA splicing defects and neurodegeneration.

The paper identifies microglia subsets in ALS brain and spinal cord, finding an undifferentiated phenotype and enrichment of interferon response microglia in aggressive cases.

The paper introduces a proteomic tool to identify protein markers for human microglial states and validates their utility in purification and differentiation.

The paper uses single-cell data to identify factors regulating an Alzheimer's disease-related microglial signature and proposes a new analytic framework for microglial classification.

This study identifies disease-enriched microglial subsets and validates compounds that modulate their states using single-cell RNA sequencing and in vitro experiments.

The paper identifies an epigenomic factor linked to reduced activated microglia that mitigates the risk of Alzheimer's disease in APOE ε4 carriers.

The paper identifies gene modules in human frontal cortex microglia associated with beta-amyloid and tau pathology in Alzheimer's disease.